Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer

  • The FDA has given accelerated approval to Amgen Inc's AMGN Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation.
  • The approval covers the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy.
  • Sotorasib is the first KRAS-targeted therapy to be approved after nearly four decades of research, the company said.
  • The approval is based on the overall response rate (ORR) and duration of response (DoR).
  • Lumakras demonstrated an ORR of 36% in the trial, with 81% of patients achieving disease control. The median DoR was ten months.
  • Continued approval for the indication depends on clinical benefit in a confirmatory trial(s).
  • Amgen has partnered with Guardant Health Inc GH and Qiagen NV QGEN to develop blood- and tissue-based companion diagnostics, respectively, for Lumakras.
  • Related content: Benzinga's Full FDA Calendar
  • Price Action: AMGN shares are up 0.40% at $236.26 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!